Gregory Lesinski, Associate Director of Basic Research at Winship Cancer Institute of Emory University, shared on LinkedIn by Sarwish Rafiq, Assistant Professor at the Emory University School of Medicine and the Winship Cancer Institute, adding:
“Congrats to Sarwish Rafiq, PhD, and team from Winship Cancer Institute of Emory University on this exciting new CAR T-cell therapy manuscript!”
Quoting Sarwish Rafiq:
“We are excited to share that our work on developing CAR/VIPRa T-cells is published in Science Magazine, Translational Medicine today! In this study, we address key limitations in CAR T-cell therapy, including suboptimal product phenotypes and insufficient engagement of endogenous immunity. We identify vasoactive intestinal peptide (VIP) signaling as an immunosuppressive axis and develop an armored CAR T-cell platform that locally delivers a VIP receptor antagonist (CAR/VIPRa). These results highlight a strategy to simultaneously enhance CAR T-cell fitness and broaden anti-tumor immunity through microenvironmental modulation.”
Title: Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models
Authors: Heather K. Lin, Dejah A. Blake, Ruby Freeman, Yujie Chen, Jaehoon Kim, Andrew M. Johnson, Kory Wells, Abhijay Mudigonda, William Liu, Poonam Yadav, Fanyuan Zeng, Abir Muhuri, Kiyoon Min, Srijon Sarkar, Yuou Wang, Subir Goyal, Ronald Christopher Roberts, Elyse Christensen, Antonio B. Ward, Brad Heller, Paul Chun, Jodi Dougan, Christopher C. Porter, Benjamin G. Barwick, Chrystal M. Paulos, Lily Yang, Anupam Patgiri, Susan Napier Thomas, Edmund K. Waller, Sarwish Rafiq
Other articles about Immuno-Oncology and CAR T-cell therapy on OncoDaily.